Table 2.
Ongoing phase 3 trials of first-line treatment with immune checkpoint inhibitors
| Trial | Agent | Histology (SQ or no-SQ) | No. of patients | Experimental arm | PD-L1 status |
| CheckMate 227 (NCT02477826) |
Nivolumab | Both | 1980 | Arm A: nivolumab. Arm B: nivolumab+ipilimumab. Arm C: SOC+nivolumab. |
All comers |
| KEYNOTE-042 (NCT02220894) |
Pembrolizumab | Both | 1240 | Arm A: pembrolizumab. Arm B: chemotherapy. |
Positive >1% |
| KEYNOTE-407 (NCT02775435) |
Pembrolizumab | SQ | 560 | Arm A: SOC. Arm B: SOC+pembrolizumab. |
All comers |
| KEYNOTE-189 (NCT02578680) |
Pembrolizumab | No-SQ | 580 | Arm A: SOC. Arm B: SOC+pembrolizumab. |
All comers |
| NEPTUNE (NCT02542293) |
Durvalumab | Both | 960 | Arm A: durvalumab+tremilimumab. Arm B: SOC. |
All comers |
| PEARL (NCT03003962) |
Durvalumab | Both | 440 | Arm A: durvalumab. Arm B: SOC. |
Positive≥25% |
| IMpower 110 (NCT02409342) |
Atezolizumab | Both | 570 | Arm A: SOC. Arm B: atezolizumab. |
Positive TC 2/3 or IC 2/3 |
| IMpower 130 (NCT02367781) |
Atezolizumab | No-SQ | 650 | Arm A: SOC. Arm B: SOC+atezolizumab. |
All comers |
| IMpower 131 (NCT02367794) |
Atezolizumab | SQ | 1025 | Arm A: SOC. Arm B: SOC+atezolizumab. |
All comers |
| IMpower 132 (NCT02657434) |
Atezolizumab | No-SQ | 568 | Arm A: SOC. Arm B: SOC+atezolizumab. |
All comers |
| IMpower 150 (NCT02366143) |
Atezolizumab | No-SQ | 1200 | Arm A: SOC+bevacizumab. Arm B: SOC+B+atezolizumab. |
All comers |
| JAVELIN LUNG 100 (NCT02576574) |
Avelumab | Both | 1095 | Arm A: SOC. Arm B: avelumab. |
Positive ≥1% |
SOC, standard of care; SQ, sqamous.